Primary and secondary endpoints
During the follow-up, eGFR (primary endpoint) did not show a statistically significant worsening over the course of the study. The baseline value was 88.10±26.47 ml/min/1.73m2 and remained stable (83.25±29.27 ml/min/1.73m2; p=0.134) until the end of the study at 36M. Values during follow-up are shown in Table 2.
The secondary endpoint includes results based on the type of oral antidiabetic drug (metformin, sulfonylureas, dipeptidyl peptidades-4 inhibitors [DPP-4i], and SGLT2i) that patients were taking. In this case, we did not observe eGFR differences during the follow-up, except in the insulin group. Patients using insulin had a worse GFR at 12M (p=0.008) that those who did not (Table 3).